Teva Pharmaceutical Industries announced positive results for its Treanda drug trial, for the treatment of lymphoma. During the trial, Treanda was given to patients with slow-growing lymphoma (non-Hodgkin lymphoma), in combination with Roche’s Rituxan. Results showed that patients treated with the combined drugs lived three years longer with no progression of their tumors, compared to those taking chemotherapy with Rituxan.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments